These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3869115)

  • 1. [In vitro effects of cefotetan on anaerobic bacteria of the genus Bacteroides fragilis group, in comparison with 8 antibiotics].
    Trevisan R; Proietti A; Pitzus E
    G Ital Chemioter; 1985; 32(2):367-70. PubMed ID: 3869115
    [No Abstract]   [Full Text] [Related]  

  • 2. [Activity of cefotetan against anaerobic bacteria].
    Sedallian A
    Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):643-4. PubMed ID: 2877431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro effects of cefotetan against Bacteroides of the fragilis group].
    Privitera G; Ortisi G; Rossi R; Vigo B
    G Ital Chemioter; 1985; 32(2):371-4. PubMed ID: 3869116
    [No Abstract]   [Full Text] [Related]  

  • 4. Activity of cefotetan against anaerobic bacteria.
    Dias MB; Jacobus NV; Tally FP; Gorbach SL
    Diagn Microbiol Infect Dis; 1986 Apr; 4(4):359-63. PubMed ID: 3457672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-antibiotic effect in Bacteroides fragilis group.
    Siverhus DJ; Edmiston CE; Clausz JC; Goheen MP
    Ann Clin Lab Sci; 1988; 18(4):326-36. PubMed ID: 3165611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro susceptibilities of anaerobic bacteria to cefmenoxime, cefotetan, and N-formimidoyl thienamycin.
    Owens WE; Finegold SM
    Antimicrob Agents Chemother; 1983 Apr; 23(4):626-9. PubMed ID: 6305265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antibacterial activity of cefotetan against Bacteroides fragilis group clinical isolates.
    Menozzi M; Avanzini P; Lecchini R; Bigi M; Chezzi C
    Chemioterapia; 1987 Jun; 6(2 Suppl):88-91. PubMed ID: 3509541
    [No Abstract]   [Full Text] [Related]  

  • 8. Cefotetan, an in vitro comparison with other antibiotics.
    Qadri SM; Belobraydic KA
    J Okla State Med Assoc; 1987 Apr; 80(4):232-5. PubMed ID: 3473192
    [No Abstract]   [Full Text] [Related]  

  • 9. A multicenter study of the in vitro antianaerobic activity of cefotetan compared with other antimicrobial agents.
    Zabransky RJ; Bobey DG; Sheikh W
    Am J Surg; 1988 May; 155(5A):47-51. PubMed ID: 3163901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial activity of the cephamycin cefotetan: an in-vitro comparison with other beta-lactam antibiotics.
    Clarke AM; Zemcov SJ
    J Antimicrob Chemother; 1983 Jan; 11 Suppl():67-72. PubMed ID: 6404881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of Bacteroides fragilis, Bacteroides thetaiotaomicron, and Fusobacteria in Antibacterial agents.
    Niederau W; Höffler U; Pulverer G
    Arzneimittelforschung; 1980; 30(12):2093-8. PubMed ID: 7194067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of cefotetan compared with that of other antimicrobial agents against anaerobic bacteria.
    Wexler HM; Finegold SM
    Antimicrob Agents Chemother; 1988 Apr; 32(4):601-4. PubMed ID: 3163908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Moxalactam: preclinical evaluation].
    Chabbert YA
    Sem Hop; 1983 Jun; 59(26):1943-6. PubMed ID: 6310782
    [No Abstract]   [Full Text] [Related]  

  • 14. Susceptibility of cefotetan and Sch 34343 to beta-lactamases produced by strains of Bacteroides that hydrolyse cefoxitin or imipenem.
    Andrew JH; Greenwood D
    J Antimicrob Chemother; 1987 May; 19(5):591-5. PubMed ID: 3497146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility testing of anaerobic bacteria.
    Citron D
    Am J Med Technol; 1983 Nov; 49(11):769-72. PubMed ID: 6316785
    [No Abstract]   [Full Text] [Related]  

  • 16. Activity in vitro of cefotetan against non-sporing anaerobes: a comparative study.
    Ruckdeschel G
    J Antimicrob Chemother; 1983 Jan; 11 Suppl():117-24. PubMed ID: 6573312
    [No Abstract]   [Full Text] [Related]  

  • 17. Susceptibility of anaerobic bacteria to five antimicrobial agents and demonstration of resistance of Bacteroides fragilis to clindamycin.
    Sofianou D; Douboyas J; Papapanagiotou J; Paradelis AG
    Methods Find Exp Clin Pharmacol; 1982; 4(3):173-7. PubMed ID: 7121128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National survey on the susceptibility of Bacteroides Fragilis Group: report and analysis of trends for 1997-2000.
    Snydman DR; Jacobus NV; McDermott LA; Ruthazer R; Goldstein EJ; Finegold SM; Harrell LJ; Hecht DW; Jenkins SG; Pierson C; Venezia R; Rihs J; Gorbach SL
    Clin Infect Dis; 2002 Sep; 35(Suppl 1):S126-34. PubMed ID: 12173121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The in-vitro activity of three long-acting cephalosporins against Bacteroides fragilis, Peptostreptococcus species and Clostridium perfringens.
    Watt B; Naden MG
    J Chemother; 1989 Jul; 1(4 Suppl):106-7. PubMed ID: 16312326
    [No Abstract]   [Full Text] [Related]  

  • 20. Cefotetan activity against Gram-negative aerobes and anaerobes.
    Moosdeen F; Maskell J; Philpott-Howard J; Williams JD
    J Antimicrob Chemother; 1983 Jan; 11 Suppl():59-65. PubMed ID: 6601657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.